Celldex Therapeutics Inc.
CLDX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.36B
Close$
$0.05
99.8% downside
Current Fair Value
99.8% downsideOvervalued by 99.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.36 Billion |
|---|---|
| Enterprise Value | $2.32 Billion |
| Earnings per Share | $-3.9 |
| Beta | 0.9 |
| Outstanding Shares | 77,840,000 |
Return
| Return on Equity | -42.07% |
|---|---|
| Return on Assets | -38.42% |
| Return on Invested Capital | -20.58% |
Valuation & Multiples
| P/E Ratio | -6.9 |
|---|---|
| PEG | -23.12 |
| Price to Sales | - |
| Price to Book Ratio | 3.33 |
| Enterprise Value to Revenue | 20724.89 |
| Enterprise Value to EBIT | -15.64 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.06
Consensus analyst estimateRevenue Estimate
$734,917
Consensus analyst estimateNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-1.02
Consensus analyst estimateRevenue Estimate
$722,636
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 192.81% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.74%▼ 108.33% |
|---|---|
| Total Invested | $43.86M▼ 98.62% |
| Investors Holding | 45▼ 225.00% |
About Celldex Therapeutics Inc.
CEO: Anthony Marucci
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeu...